Catalyst Wire Dossier Catalyst Wire Dossier

Recombinant Human Serum Albumin/Interferon alpha-2a Fusion Protein

· Beijing Bio-Fortune Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Recombinant Human Serum Albumin/Interferon alpha-2a Fusion Protein, covering 2014-11-17 to 2014-11-17. Get the full timeline:

Most recent: Clinical Trial Update: Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients [Phase 1, Phase 2]

See pricing